GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » EV-to-FCF

Next Science (ASX:NXS) EV-to-FCF : -3.34 (As of May. 17, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Next Science EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Next Science's Enterprise Value is A$79.47 Mil. Next Science's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.79 Mil. Therefore, Next Science's EV-to-FCF for today is -3.34.

The historical rank and industry rank for Next Science's EV-to-FCF or its related term are showing as below:

ASX:NXS' s EV-to-FCF Range Over the Past 10 Years
Min: -20.88   Med: -10.84   Max: -2.06
Current: -4.13

During the past 6 years, the highest EV-to-FCF of Next Science was -2.06. The lowest was -20.88. And the median was -10.84.

ASX:NXS's EV-to-FCF is ranked worse than
100% of 521 companies
in the Drug Manufacturers industry
Industry Median: 24.13 vs ASX:NXS: -4.13

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Next Science's stock price is A$0.315. Next Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.104. Therefore, Next Science's PE Ratio for today is At Loss.


Next Science EV-to-FCF Historical Data

The historical data trend for Next Science's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science EV-to-FCF Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -15.55 -13.32 -18.84 -7.78 -3.64

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.84 - -7.78 - -3.64

Competitive Comparison of Next Science's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Next Science's EV-to-FCF falls into.



Next Science EV-to-FCF Calculation

Next Science's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=79.474/-23.787
=-3.34

Next Science's current Enterprise Value is A$79.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Next Science  (ASX:NXS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Next Science's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.315/-0.104
=At Loss

Next Science's share price for today is A$0.315.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.104.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Next Science EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Next Science's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines